Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Drops By 16.7%

bioAffinity Technologies, Inc. (NASDAQ:BIAFGet Free Report) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 226,200 shares, a decline of 16.7% from the October 31st total of 271,400 shares. Based on an average daily trading volume, of 123,400 shares, the days-to-cover ratio is currently 1.8 days. Approximately 2.4% of the shares of the company are short sold.

bioAffinity Technologies Stock Performance

Shares of NASDAQ:BIAF traded down $0.11 during trading on Monday, hitting $1.11. 42,945 shares of the stock traded hands, compared to its average volume of 137,609. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a 52-week low of $1.03 and a 52-week high of $3.62. The company has a fifty day moving average price of $1.56 and a two-hundred day moving average price of $1.89. The company has a market cap of $17.22 million, a price-to-earnings ratio of -1.48 and a beta of 3.10.

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently bought a new position in bioAffinity Technologies stock. Ground Swell Capital LLC bought a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAFFree Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned about 0.20% of bioAffinity Technologies as of its most recent SEC filing. 1.64% of the stock is owned by institutional investors.

bioAffinity Technologies Company Profile

(Get Free Report)

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.

Read More

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.